Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<IPO>TENNOR THERAP-B (06872.HK) Closes Subscription at Noon; Reportedly 9,000x+ Oversubscribed in Public Offering
Recommend 4 Positive 4 Negative 4 |
||||
|
||||
|
TENNOR THERAP-B (06872.HK), a biotechnology company nearing commercialization, closes its subscription at noon today (19th). Its Hong Kong public offering was preliminarily oversubscribed by 9,026x, attracting 278,000 subscribers, local media, citing sources, reported. Based on this, TENNOR THERAP-B is the second most oversubscribed new listing on the Main Board this year, trailing only ROBOTPHOENIX (06871.HK), which recorded 14,800x oversubscription. TENNOR THERAP-B plans to globally offer 8.2806 million H shares. The offer price is HKD75.7 per share. Based on a board lot of 50 shares, the entry fee per lot is approximately HKD3,823.17. The listing is expected to raise net proceeds of approximately HKD558 million and is scheduled to debut this Friday (22nd). The joint sponsors are CITIC Securities and ABCI. Five cornerstone investors were introduced in this offering, subscribing for shares equivalent to approximately USD29.8 million (approximately HKD234 million) in aggregate. WUXI APPTEC (02359.HK) is a pre-IPO investor of the company. Upon completion of the global offering, WUXI APPTEC will hold approximately 5.5% of the company's total issued share capital through WuXi Fund. Auto-translated by AI This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. More Details
AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
